Teriflunomide

Study	Country Study period	Population source	Exposure definition	Non-exposure definition	Sample size	Rmk
Barataud-Reilhac A (Control exposed to IFN or GLA), 2019	France 2014 - 2016	All 15 to 49 year-old French women, identified as having Multiple Sclerosis (MS), not sterile, and benefiting from health insurance	Pregnant MS women exposed to teriflunomide, i.e woman had taken it during pregnancy or did not follow the appropriate recommendations (accelerated disposal procedure) after treatment stop.	exposed to other treatment, sick Pregnant MS women exposed to interferons or glatiramer acetate (IFN-GA) during pregnancy.	47 / 673
Barataud-Reilhac A (Control unexposed, sick), 2019	France 2014 - 2016	All 15 to 49 year-old French women, identified as having Multiple Sclerosis (MS), not sterile, and benefiting from health insurance.	Pregnant women exposed to teriflunomide, i.e woman had taken it during pregnancy or did not follow the appropriate recommendations (accelerated disposal procedure) after treatment stop.	unexposed, sick Pregnant women with no treatment (NOTT).	47 / 1538

Study	Country Study period	Case	Control	Sample size	Rmk

6 studies, not fulfilled eligibility criteria, were excluded. See excluded tab for the list of these studies and reason of exclusion.